Role of Sympathetic Activation in Ischemia Reperfusion Injury
NCT ID: NCT04479813
Last Updated: 2022-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
46 participants
INTERVENTIONAL
2015-07-08
2022-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Normothermia in Patients With Acute Cerebral Damage
NCT00491192
Field Randomization of Nerinetide (NA-1) Therapy in Early Responders
NCT02315443
Inhaled Nitric Oxide in Brain Injury
NCT03260569
Dexmedetomidine and Subarachnoid Haemorrhage
NCT01664520
Effect of Pharmacological Interventions on Systolic Blood Pressure Drops (SynABPM 2 Proof-of-concept)
NCT05729724
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This medication acts by reducing the activity of nerves believed to be involved in the conditioning process. The placebo pill, designed to have no effect, will be used as a comparison. Comprehensive tests will occur which include Microneurography, Endothelial function ,Blood Sampling, Temporary block of arm blood flow and Remote conditioning
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No conditioning + placebo
Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.
placebo
Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
No conditioning + moxonidine
Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.
Moxonidine 0.2 MG
Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
Remote pre-conditioning + placebo
Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.
placebo
Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
Remote pre-conditioning + moxonidine
Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.
Moxonidine 0.2 MG
Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Moxonidine 0.2 MG
Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
placebo
Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Royal Perth Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Markus Schlaich
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Markus Schlaich, MD,FAHA,FESC
Role: PRINCIPAL_INVESTIGATOR
Royal Perth Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dobney Hypertension Centre
Perth, , Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REG 15-021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.